Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 0098 • ACR Convergence 2022
Delays in Access to Specialized Care and Diagnosis in Patients with Systemic Lupus Erythematosus
Alain Sanchez-Rodriguez¹, Jose A Meade-Aguilar², Jeffrey X. Yang², Gabriel Figueroa Parra², Shirley-Ann Osei-Onomah², Rachel Giblon³, Hannah Langenfeld⁴, Alanna Chamberlain², Cynthia Crowson⁵ and Ali Duarte-Garcia², ¹Division of Rheumatology, Mayo Clinic, Rochester, MN, ²Mayo Clinic, Rochester, MN, ³Mayo Clinic, Rochester, MN, Rochester, MN, ⁴Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, ⁵Mayo Clinic, Eyota, MN
Background/Purpose: Delays in access to specialized care and diagnosis of systemic lupus erythematosus (SLE) are associated with poor outcomes. Prior studies rely mostly on cross-sectional…
Abstract Number: 0319 • ACR Convergence 2022
Factors Associated with Worsening Interstitial Fibrosis/Tubular Atrophy in Lupus Nephritis Patients Undergoing Repeat Kidney Biopsy
Daming Shao¹, Alejandra Londoño Jimenez², Maria Auxiliadora Salgado Guerrero³, Anna Broder⁴ and Shudan Wang⁵, ¹Albert Einstein College of Medicine/Jacobi Medical Center, Bronx, NY, ²McFarland Clinic, Ames, IA, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Hackensack University Medical Center, Hackensack, NJ, ⁵Montefiore Medical Center / Albert Einstein College of Medicine, New York, NY
Background/Purpose: Lupus nephritis (LN) is one of the most severe manifestations of systemic lupus erythematosus (SLE). Approximately 10 to 30% of patients with LN progress…
Abstract Number: 0337 • ACR Convergence 2022
Expanded Autoantibody Profiling in Incomplete Lupus Erythematosus
Rebecca Wood¹, Catriona Wagner², Carla J. Guthridge³, Joel Guthridge³, Steve Wallace⁴, Pennina R Safer⁵ and Judith James³, ¹Oklahoma Medical Research Foundation, Edmond, OK, ²Oklahoma Medical Research Foundation, Santa Cruz, CA, ³Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Immunarray, Richmond, ⁵Immunarray, Rehovot, Israel
Background/Purpose: Incomplete lupus erythematosus (ILE) involves clinical and/or serologic manifestations consistent with but insufficient for SLE classification. While a subset of ILE patients transition to…
Abstract Number: 0354 • ACR Convergence 2022
Clinical and Economic Characterization of Systemic Lupus Erythematosus Patients by Cumulative Corticosteroid Dose over 1 Year: Real-World Observation of Commercially Insured Adults in the United States
Sandra Sze-jung Wu¹, Allison Perry², Helen Varker³, Rich Bizier³, Liisa Palmer³ and Gary Bryant⁴, ¹AstraZeneca, Hockessin, DE, ²IBM Watson Health, New York, NY, ³Merative, Cambridge, MA, ⁴AstraZeneca, New Castle, DE
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex, heterogeneous disease associated with periods of flares. Identifying patients at risk of severe disease and associated resource…
Abstract Number: 0538 • ACR Convergence 2022
Contemporary Incidence of Lupus Nephritis Among Patients with Systemic Lupus Erythematosus in the United States
April Jorge¹, Baijun Zhou¹, Jacquelyn Nestor¹, yuqing zhang² and Hyon Choi³, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Quincy, MA, ³MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA
Background/Purpose: Lupus nephritis is a leading cause of morbidity in patients with systemic lupus erythematosus (SLE). We sought to determine the incidence of lupus nephritis…
Abstract Number: 0641 • ACR Convergence 2022
IL-4 Receptor Signaling and IKAROS Transcriptomic Program Maintains Naïve B-cell Quiescence and Antagonizes SLE
John Mountz, Min Gao, Shanrun Lui, Walter Chatham and Hui-Chen Hsu, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Factors that promote B-cell quiescence and homeostasis at the transitional (Tr) and naive stages of B cells to prevent excessive TLR7 and type I…
Abstract Number: 0661 • ACR Convergence 2022
Cutaneous Type I IFN Responses in Systemic Lupus Erythematosus Are Associated with Inflammatory Phenotype and Altered Wound Healing Function of Lupus Fibroblasts from Non-Lesional Skin
Lisa Abernathy-Close, Suzanne Shoffner-Beck, Annie Lu, Amanda Victory, Amy Hurst, Craig Dobry, Rachael Wasikowski, Johann Gudjonsson, Alex Tsoi and J. Michelle Kahlenberg, University of Michigan, Ann Arbor, MI
Background/Purpose: Cutaneous lupus erythematosus (CLE) is a heterogenous, disfiguring, and difficult-to-treat manifestation of systemic lupus erythematosus (SLE) with scar formation in CLE subtypes such as…
Abstract Number: 0819 • ACR Convergence 2022
Connective Tissue Disease-Related Interstitial Lung Disease: Trends from an Urban Academic Tertiary Care Center
Anchal Sabharwal¹, Yuanqing Liu¹, Yazmin Rustomji¹ and Sonali Khandelwal², ¹Rush University Medical Center, Chicago, IL, ²Rush University, Chicago, IL
Background/Purpose: Connective tissue diseases (CTDs) are a category of autoimmune disease in which interstitial lung disease (ILD) is a common pulmonary manifestation. Due to the…
Abstract Number: 0965 • ACR Convergence 2022
Pregnancy Outcomes in a Diverse Lupus Cohort
Julia Simard¹, Emily Liu², Eliza Chakravarty³, Amadeia Rector¹, Miranda Cantu⁴, Daniel Kuo⁵, Gary Shaw⁶, Maurice Druzin⁶, Michael Weisman⁷ and Monique Hedderson², ¹Stanford University School of Medicine, Palo Alto, CA, ²Kaiser Permanente Northern California’s Division of Research, Oakland, CA, ³Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Global Lupus Support Group, Portage, MI, ⁵Kaiser Permanente, Redwood City Medical Center, Redwood City, CA, ⁶Stanford University School of Medicine, Palo Alto, ⁷Adjunct Professor of Medicine, Stanford University; Distinguished Professor of Medicine Emeritus, David Geffen School of Medicine at UCLA, Los Angeles, CA
Background/Purpose: Although the overall systemic lupus (SLE) patient population is racially and ethnically diverse, many study populations are homogeneous. We assembled a diverse group of…
Abstract Number: 0987 • ACR Convergence 2022
A Randomized Placebo-Controlled Phase 1 Study in Healthy Adult Volunteers of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ALPN-303, a Potent Dual BAFF/APRIL Antagonist for the Treatment of Systemic Lupus Erythematosus and Other Autoantibody-Associated Diseases
Stacey Dillon¹, Pille Harrison², Jason Lickliter³, Kristi Manjarrez¹, Alina Smith¹, Mary Lessig¹, Lori Blanchfield¹, Russell Sanderson¹, Allison Chunyk¹, Tiffany Blair¹, Amanda Enstrom¹, Martin Wolfson¹, Mark Rixon¹, Hany Zayed⁴, Rupert Davies¹ and Stanford Peng¹, ¹Alpine Immune Sciences, Seattle, WA, ²Alpine Immune Sciences, Taunton, United Kingdom, ³Nucleus Network, Melbourne, Australia, ⁴Alpine Immune Sciences, San Francisco, CA
Background/Purpose: B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL) are tumor necrosis factor (TNF) superfamily members that bind TACI (transmembrane activator and CAML…
Abstract Number: 1003 • ACR Convergence 2022
Does LLDAS Definition Match the Rheumatologist Opinion? The First Visit Evaluation of a Longinudital Spanish Multicenter Study to Assess Reasons of Disagreement
Coral Mouriño Rodriguez¹, Irene Altabas Gonzalez¹, Iñigo Rúa-Figueroa², Norman Jimenez³, Francisco Rubiño⁴, Iñigo Hernandez Rodriguez¹, Raul Menor Almagro⁵, Esther Uriarte Isacelaya⁶, Eva Tomero Muriel⁷, Tarek Carlos Salman-Monte⁸, Irene Carrion Barbera⁹, maria Galindo¹⁰, Esther Rodriguez Almaraz¹⁰, Luis Ines Sousa¹¹ and Jose M Pego-Reigosa¹², ¹Complejo Hospitalario Universitario de Vigo, Vigo, Spain, ²Hospital Universitario Dr Negrín, Las Palmas de Gran Canaria, Spain, ³IRIDIS Group, Vigo, Spain, ⁴Hospital Universitario de Jerez de la Frontera, Jerez de la frontera, Spain, ⁵Hospital Jerez de la Frontera, Cádiz, Spain, ⁶Hospital Universitario Donostia, Donostia, Spain, ⁷Hospital Universitario La Princesa, Madrid, Spain, ⁸Hospital del Mar/Parc de Salut Mar-IMIM/UEC-AIS, Barcelona, Spain, ⁹Hospital del Mar, Rheumatology, Barcelona, Spain, ¹⁰Hospital Universitario 12 de Octubre, Madrid, Spain, ¹¹Centro Hospitalar e Universitario de Coimbra, Coimbra, Portugal, ¹²Hospital Meixoeiro, Vigo, Spain
Background/Purpose: Treat to Target strategies are necessary in Systemic Lupus Erythematosus (SLE). They are difficult to establish due to the heterogeneity of the disease. The…
Abstract Number: 1221 • ACR Convergence 2022
Multi-Center Validation of Cell-Bound Complement Activation Products and a Multianalyte Assay Panel Distinguishing Systemic Lupus Erythematosus from Primary Fibromyalgia
Mark Rudolph¹, Scott Rey¹, Alan Kivitz², Stuart Silverman³, Roland Staud⁴ and Roberta Alexander¹, ¹Exagen, Inc., Vista, CA, ²Department of Rheumatology, Altoona Center for Clinical Research, Duncansville, PA, ³Cedars-Sinai Medical Center, Los Angeles, CA, ⁴University of Florida, Gainesville, FL
Background/Purpose: A 2016 article in Lupus Science & Medicine (Wallace et al. 2016) described the ability of cell-bound complement activation products (CB-CAPs) on their own--…
Abstract Number: 1373 • ACR Convergence 2022
Increased Patient Contact May Mitigate Flares Among jSLE Patients
Jessica Fennell, Deanna Jannat-Khah, DrPH, MSPH and karen onel, Hospital for Special Surgery, New York, NY
Background/Purpose: Optimizing jSLE management is crucial to prevent flares as the damage sustained during flares contributes to lifelong morbidity and mortality. The onset of the…
Abstract Number: 1448 • ACR Convergence 2022
Utility of Digital Signals and Patient Reported Data Gathered in a Decentralized Study to Predict SLE Patient-Reported Flares
Eldon Jupe¹, Gerald Lushington², Mohan Purushothaman¹, Fabricio Pautasso¹, Georg Armstrong¹, Arif Sorathia¹, Jessica Crawley¹, Vijay Nadipelli³, Bernie Rubin⁴, Ryan Newhardt¹, Melissa Munroe¹ and Brett Adelman¹, ¹Progentec Diagnostics, Inc., Oklahoma City, OK, ²Progentec Diagnostics, Inc., Oklahoma City, OR, ³GlaxoSmithKline, Philadelphia, PA, ⁴GlaxoSmithKline, US Medical Affairs and Immuno-inflammation, Durham, NC
Background/Purpose: Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease characterized by varied immune dysregulation. SLE patients often experience episodic flares, leading to organ damage…
Abstract Number: 1467 • ACR Convergence 2022
Dickkopf Homolog 3 (DKK3) as a Prognostic Marker in Lupus Nephritis: A Prospective Monocentric Experience
Savino Sciascia¹, Alice Barinotti², Massimo Radin², Irene Cecchi¹, Elisa Menegatti², Vittorio Modena², Daniela Rossi², Simone Baldovino², Roberta Fenoglio² and Dario Roccatello², ¹University of Turin, Torino, Italy, ²University of Turin, Turin, Italy
Background/Purpose: Lupus Nephritis (LN) is a major cause of mortality/morbidity in patients affected by Systemic Lupus Erythematosus (SLE). Reliable prognostic markers, especially related to the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].